Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Ben F. M. Wijnen, Frederick W. Thielen, Steef Konings, Talitha Feenstra, Mark van der Gaag, Wim Veling, Lieuwe de Haan, Helga Ising, Mickaël Hiligsmann, Silvia M. A. A. Evers, Filip Smit, Joran Lokkerbol

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors.
Original languageEnglish
JournalExpert review of pharmacoeconomics & outcomes research
DOIs
Publication statusPublished - 2019

Cite this

Wijnen, Ben F. M. ; Thielen, Frederick W. ; Konings, Steef ; Feenstra, Talitha ; van der Gaag, Mark ; Veling, Wim ; de Haan, Lieuwe ; Ising, Helga ; Hiligsmann, Mickaël ; Evers, Silvia M. A. A. ; Smit, Filip ; Lokkerbol, Joran. / Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. In: Expert review of pharmacoeconomics & outcomes research. 2019.
@article{8613951410c94849bd71a2d5061b3a19,
title = "Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis",
abstract = "Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors.",
author = "Wijnen, {Ben F. M.} and Thielen, {Frederick W.} and Steef Konings and Talitha Feenstra and {van der Gaag}, Mark and Wim Veling and {de Haan}, Lieuwe and Helga Ising and Micka{\"e}l Hiligsmann and Evers, {Silvia M. A. A.} and Filip Smit and Joran Lokkerbol",
year = "2019",
doi = "10.1080/14737167.2019.1632194",
language = "English",
journal = "Expert review of pharmacoeconomics & outcomes research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",

}

Wijnen, BFM, Thielen, FW, Konings, S, Feenstra, T, van der Gaag, M, Veling, W, de Haan, L, Ising, H, Hiligsmann, M, Evers, SMAA, Smit, F & Lokkerbol, J 2019, 'Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis' Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2019.1632194

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. / Wijnen, Ben F. M.; Thielen, Frederick W.; Konings, Steef; Feenstra, Talitha; van der Gaag, Mark; Veling, Wim; de Haan, Lieuwe; Ising, Helga; Hiligsmann, Mickaël; Evers, Silvia M. A. A.; Smit, Filip; Lokkerbol, Joran.

In: Expert review of pharmacoeconomics & outcomes research, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

AU - Wijnen, Ben F. M.

AU - Thielen, Frederick W.

AU - Konings, Steef

AU - Feenstra, Talitha

AU - van der Gaag, Mark

AU - Veling, Wim

AU - de Haan, Lieuwe

AU - Ising, Helga

AU - Hiligsmann, Mickaël

AU - Evers, Silvia M. A. A.

AU - Smit, Filip

AU - Lokkerbol, Joran

PY - 2019

Y1 - 2019

N2 - Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors.

AB - Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068155768&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31195900

U2 - 10.1080/14737167.2019.1632194

DO - 10.1080/14737167.2019.1632194

M3 - Article

JO - Expert review of pharmacoeconomics & outcomes research

JF - Expert review of pharmacoeconomics & outcomes research

SN - 1473-7167

ER -